Navigation Links
Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
Date:3/20/2009

BOSTON, March 20 /PRNewswire/ -- Replikins, Ltd. announced today that data recently published from Harvard-CDC and Scripps-Crucell in Nature(1) and Science(2) confirms the 2001 discoveries by Dr. Samuel and Elenore Bogoch of peptides in the hemagglutinin unit of influenza, which they named Replikins, which are shared across flu strains, conserved over time, associated with the last three pandemics of 1918, 1957 and 1968, as well as current H5N1 outbreaks, and are the basis of broad spectrum flu vaccines. The Replikins sequences, as specified by the Bogoches, are the subject of granted patents from 2001 and a 2005 monograph(3).

The amino acid contact points between the neutralizing antibody and the virus that the Harvard-CDC and Scripps-Crucell investigators both observed, out of over 500 possible sites, are in the influenza Replikins. The confirming groups' data also verified the Bogoch 2001 findings of conservation of these very Replikins peptides over decades, and the sharing of Replikins between strains of influenza, making general flu vaccines possible for the first time.

The Replikins peptides, associated with rapid replication, are quantitatively trackable and predictive of the intensity, timing, and country of outbreak. The company's FluForecast(R) software has correctly predicted recent H5N1 outbreaks and the countries in which they were going to occur(4).

Replikins, which are quantitatively related to lethality in influenza and other infectious diseases, such as HIV, anthrax, and malaria, as well as cancer, and a range of animal diseases, are the subject of synthetic vaccines in development at the Company.

1. Sui, J. et al. "Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses." Nature Structural and Molecular Biology, published online: Feb. 22, 2009, doi:10.1038-nsmb.1566.

2. Ekeirt, D.C. et al. "Antibody Recognition of a Highly Conserved Influenza Virus Epitope." Science DOI: 10.1126-science.1171491, Science Published online, Feb. 26, 2009.

3. Bogoch S. and Bogoch, E.S. "Replikins, the Chemistry of Rapid Replication. With examples in influenza, HIV, AIDS, SARS, Malaria, and Cancer." Begell House, Inc., New York, Wallingford, U.K. ISBN 1-56700-200-5, 2005.

4. Online (replikins.com): see "Replikins Press," 2006 - 2008. (Press release #12: Indonesia Reports Experiencing Human H5N1 Mortality Increase, as Predicted Last Year by Replikins' FluForecast(R) Quantitative Virus Analysis; June 8, 2007).

REPLIKINS, Ltd., 38 the Fenway, Boston, MA 02215

http://www.replikins.com

Contact: jjosephson@replikins.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA
2. Confirmation of HGT Business Day - 18th November 2008
3. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
4. Confirmation of Strong Growth Over the First Half of 2008
5. Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus
6. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
7. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
8. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
9. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
10. DaVita Launches Flu Fighter Program in Support of National Influenza Week
11. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... Lady had been battling arthritis since the age of ... left knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen of ... her cruciate ligament and help with the pain of Lady’s arthritis. Dr Christiansen suggested ...
(Date:5/24/2016)... ... ... Last week, Callan Capital, an integrated wealth management firm specializing in asset ... Diego Life Science event at the Estancia La Jolla Resort and Spa. , Over ... Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former CEO ...
(Date:5/23/2016)... 23, 2016 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2016. The cash dividend of $0.24 ... 2016 to stockholders of record as of the close of ... subject to approval of the Board of Directors and may ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
Breaking Biology Technology:
(Date:3/15/2016)... Yissum Research Development Company of the Hebrew University ... University, announced today the formation of Neteera Technologies ... biological indicators. Neteera Technologies has completed its first round ... Neteera,s ... from sweat ducts, enables reliable and speedy biometric identification, ...
(Date:3/11/2016)... , March 11, 2016 http://www.apimages.com ) - ... reference: Picture is available at AP Images ( http://www.apimages.com ) - ... will be used to produce the new refugee identity cards. DERMALOG ... innovations, at CeBIT in Hanover next week.   ... DERMALOG will be used to produce the new refugee identity cards. ...
(Date:3/10/2016)... BLUE BELL, Pa. , March 10, 2016   ... U.S. Customs and Border Protection (CBP) is testing ... in San Diego to help identify ... United States . The test, designed to help determine ... outdoor, pedestrian environment, began in February and will run until ...
Breaking Biology News(10 mins):